The short version of size-exclusion chromatography fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
== Methodology == Operando spectroscopy is a class of methodology, rather than a specific spectroscopic technique such as FTIR or NMR. Operando spectroscopy is a logical technological progress in situ studies. Catalyst scientists would ideally like to have a "motion picture" of each catalytic cycle, whereby the precise bond-making or bond-breaking events taking place at the active site are known; this would allow a visual model of the mechanism to be constructed. The ultimate goal is to determine the structure-activity relationship of the substrate-catalyst species of the same reaction. Having two experiments—the performing of a reaction plus the real-time spectral acquisition of the reaction mixture—on a single reaction facilitates a direct link between the structures of the catalyst and intermediates, and of the catalytic activity/selectivity. Although monitoring a catalytic process in situ can provide information relevant to catalytic function, it is difficult to establish a perfect correlation because of the current physical limitations of in situ reactor cells. Complications arise, for example, for gas phase reactions which require large void volumes, which make it difficult to homogenize heat and mass within the cell. The crux of a successful operando methodology, therefore, is related to the disparity between laboratory setups and industrial setups, i.e., the limitations of properly simulating the catalytic system as it proceeds in industry.
==== Pharmacokinetics of urea derivatives ==== Regorafenib and sorafenib reach mean peak plasma level in about 3 or 4 hours after a single oral dose. A high-fat meal decreases their absorption, while a low-fat meal may increase it, in comparison to taking the drugs in a fasting condition. In vitro protein binding is 99,5% for both drugs. The drugs are mainly metabolized in the liver by oxidative metabolism of CYP3A4, and glucuronidized by UGT1A9. Their half-life ranges from 20 to 48 hours. Most of the administered dose should be out of the system in around 14 days. The drugs are mostly excreted in faeces, around 70-80%, but also in urine.
== Helicity (polarization) of neutrinos, electrons and positrons emitted in beta decay == After the discovery of parity non-conservation (see § History), it was found that, in beta decay, electrons are emitted mostly with negative helicity, i.e., they move, naively speaking, like left-handed screws driven into a material (they have negative longitudinal polarization). Conversely, positrons have mostly positive helicity, i.e., they move like right-handed screws. Neutrinos (emitted in positron decay) have negative helicity, while antineutrinos (emitted in electron decay) have positive helicity. The higher the velocity (energy) of the particles, the higher their helicity polarization; this reflects the absolute chirality selection in W boson decay.
From analysis of the existing small treatment trials of cervical artery dissection (carotid and vertebral) it appears that aspirin and anticoagulation (heparin followed by warfarin) are equally effective in reducing the risk of further stroke or death. Anticoagulation is regarded as more powerful than antiplatelet therapy, but anticoagulants may increase the size of the hematoma and worsen obstruction of the affected artery. Anticoagulation may be relatively unsafe if a large stroke has already occurred, as hemorrhagic transformation is relatively common, and if the dissection extends into V4 (carrying a risk of subarachnoid hemorrhage). Anticoagulation may be appropriate if there is rapid blood flow (through a severely narrowed vessel) on transcranial doppler despite the use of aspirin, if there is a completely occluded vessel, if there are recurrent stroke-like episodes, or if free-floating blood clot is visible on scans. Warfarin is typically continued for 3–6 months, as during this time the flow through the artery usually improves, and most strokes happen within the first 6 months after the development of the dissection. Some regard 3 months as sufficient. Professional guidelines in the UK recommend that patients with VA dissection should be enrolled in a clinical trial comparing aspirin and anticoagulation if possible. American guidelines state that the benefit of anticoagulation is not currently established.
=== Polyamine biosynthesis === Another major role of SAM is in polyamine biosynthesis. Here, SAM is decarboxylated by adenosylmethionine decarboxylase to form S-adenosylmethioninamine. S-Adenosylmethioninamine then donates its n-propylamine group in the biosynthesis of polyamines such as spermidine and spermine from putrescine. SAM is required for cellular growth and repair. It is also involved in the biosynthesis of several hormones and neurotransmitters that affect mood, such as epinephrine. Methyltransferases are also responsible for the addition of methyl groups to the 2′ hydroxyls of the first and second nucleotides next to the 5′ cap in messenger RNA.
Sources: en.wikipedia.org
A synarthrosis is a type of joint which allows no movement under normal conditions. Sutures and gomphoses are both synarthroses. Joints which allow more movement are called amphiarthroses or diarthroses. Syndesmoses are considered to be amphiarthrotic, because they allow a small amount of movement.
=== Underdiagnosis === Despite increasing clinical documentation, symptomatic Tarlov cysts remain frequently underdiagnosed. This has been attributed to persistent misconceptions in clinical practice and the common perception that these cysts represent incidental findings. Radiologists often omit documenting them on MRI reports or describe them as clinically insignificant, which may contribute to delayed or missed diagnoses. Smaller cysts, in particular, are more likely to be overlooked.
=== Discontinued === Alniditan (R-91274) – serotonin 5-HT1B and 5-HT1D receptor agonist – migraine [72] Avitriptan (BMS-180048) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [73] Bezisterim (HE-3286; NE-3107; Triolex; 17α-ethynyl-5-androstene-3β,7β,17β-triol) – undefined mechanism of action (synthetic androstenetriol analogue and anti-inflammatory) – migraine [74] BI-44370 (BI44370) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [75] Botulinum toxin A topical (RT-001) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [76] Carisbamate (Comfyde; JNJ-10234094; RWJ-333369; YKP-509) – unknown mechanism of action – migraine [77] Dasolampanel (NGX-426) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [78] Dextromethorphan/quinidine (DXM/Q; AVP-923; Neurodex; Nuedexta; Zenvia) – combination of dextromethorphan (various actions) and quinidine (various actions) – migraine [79] Dihydroergocryptine (SRN-001) – non-selective monoamine receptor modulator and ergoline – migraine [80] Donitriptan (F-11356) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [81] Dotarizine (Dotaricin; FI-6026) – calcium channel blocker and serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptor antagonist – migraine [82] Dronabinol (Δ9-THC; Δ9-tetrahydrocannabinol; Deltanyne; Elevat; Marinol) – cannabinoid CB1 and CB2 receptor agonist – migraine [83] Ergotamine inhalation (Tempo-ergotamine) – non-selective monoamine receptor modulator and ergoline – migraine [84] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) – migraine [85] Ethinylestradiol/levonorgestrel (DP3; DR-103; DR-105; LoSeasonique; Seasonique) – combination of ethinylestradiol (an estrogen) and levonorgestrel (a progestogen) and a combined oral contraceptive – menstrual migraine [86] (S)-Ethylisothiouronium diethylphosphate (Difetur; MTR-104; MTR-105; MTR-106; MTR-107; MTR-108; Raviclust; Ravimig; Raviten) – nitric oxide synthase (NOS) inhibitor [87] Fremanezumab (Ajovy; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache, headache [88] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) – migraine [89] Gabapentin enacarbil (1838262; ASP8825; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) – migraine [90] Ganaxolone (CCD-1042; Ztalmy) – GABAA receptor positive allosteric modulator and neurosteroid – migraine [91] HTL-0022562 (BHV-3100; HTL-22562) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [92] IS-159 – serotonin 5-HT1B and 5-HT1D receptor agonist – migraine [93] Lacosamide (ADD-234037; Erlosamide; Harkoseride; SPM-927; SPM-929; Vimpat; Vimpato) – various actions – migraine [94] Lanepitant (LY-303870) – neurokinin NK1 receptor antagonist – migraine [95] Lidocaine transdermal patch (ADL-87223; LidoPAIN) – sodium channel blocker – headache [96] Lornoxicam (Bosporon; Chlortenoxicam; HN-10000; RO-139297; Safem; TS-110; Xefo) – COX inhibitor/NSAID – migraine [97] LY-2300559 – metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist – migraine [98] LY-334370 – serotonin 5-HT1F receptor agonist and triptan – migraine [99] MEDI-0618 – monoclonal antibody against protease-activated receptor 2 (PAR2) – migraine [100] Olcegepant (BIBN-4096; BIBN-4096BS) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [101] Oxytocin (TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – migraine [102] Perampanel (E-2007; ER-155055-90; Fycompa) – AMPA receptor antagonist – migraine [103] PF-5180999 (PF-05180999) – phosphodiesterase PDE2 inhibitor – migraine [104] PNU-142633 (PNU-142633F) – serotonin 5-HT1D receptor agonist – cluster headache, headache, migraine [105] Prochlorperazine inhalation (AZ-001) – typical antipsychotic (non-selective monoamine receptor modulator) – migraine [106] Propisergide (ergalgin) – serotonin receptor modulator and ergoline – migraine Propofol phosphate (Neuprox; propofol prodrug) – GABAA receptor positive allosteric modulator (propofol prodrug) – migraine [107] Research programme: migraine therapy - Orexo (OX-40; OX641) – undefined mechanism of action – migraine [108] Selurampanel (BGG-492; BGG-492A) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [109] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist and ergoline – migraine [110] Telcagepant (MK-0974) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [111] Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [112] Tizanidine (AN-021A; AN-021; DS-103282; Sirdalud; Ternelin; Zanaflex) – α2-adrenergic receptor agonist – migraine [113] Tonabersat (SB-220453; USL-260; Xiflam) – connexin 43 (GJA1) inhibitor – migraine [114] Zolmitriptan inhalation (CVT-427) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [115] Zonisamide (AD-810; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran) – calcium channel blocker, sodium channel blocker, and other actions – migraine [116]
Once again, RuBisCO activase can promote the release of these analogs from the catalytic sites and maintain the enzyme in a catalytically active form. However, at high temperatures, RuBisCO activase aggregates and can no longer activate RuBisCO. This contributes to the decreased carboxylating capacity observed during heat stress.
Sources: en.wikipedia.org
Currently, FDA have already approved a number of diagnostics assays utilizing microarrays: Agendia's MammaPrint assays can inform the breast cancer recurrence risk by profiling the expression of 70 genes related to breast cancer; Autogenomics INFNITI CYP2C19 assay can profile genetic polymorphisms, whose impacts on therapeutic response to antidepressants are great; and Affymetrix's CytoScan Dx can evaluate intellectual disabilities and congenital disorders by analyzing chromosomal mutation. In the future, the diagnostic tools for cancer will likely to focus on the Next Generation Sequencing (NGS). By utilizing DNA and RNA sequencing to do cancer diagnostics, technology in the field of molecular diagnostics tools will develop better. Although NGS throughput and price have dramatically been reduced over the past 10 years by roughly 100-fold, we remain at least 6 orders of magnitude away from performing deep sequencing at a whole genome level. Currently, Ion Torrent developed some NGS panels based on translational AmpliSeq, for example, the Oncomine Comprehensive Assay. They are focusing on utilizing deep sequencing of cancer-related genes to detect rare sequence variants. Molecular diagnostics tool can be used for cancer risk assessment. For example, the BRCA1/2 test by Myriad Genetics assesses women for lifetime risk of breast cancer. Also, some cancers are not always employed with clear symptoms. It is useful to analyze people when they do not show obvious symptoms and thus can detect cancer at early stages.
== External links == Basel, Yochai; Hassner, Alfred (2001). "Imidazole and Trifluoroethanol as Efficient and Mild Reagents for Destruction of Excess Di-tert-butyl Dicarbonate [(BOC)2O]". Synthesis. 2001 (4): 0550. doi:10.1055/s-2001-12350. S2CID 97029361.
The atherosclerotic process is not well understood. Atherosclerosis is associated with inflammatory processes in the endothelial cells of the vessel wall associated with retained low-density lipoprotein (LDL) particles. This retention may be a cause, an effect, or both of the underlying inflammatory process. The presence of the plaque induces the muscle cells of the blood vessel to stretch, compensating for the additional bulk. The endothelial lining then thickens, increasing the separation between the plaque and the lumen. The thickening somewhat offsets the narrowing caused by the plaque's growth. Moreover, it causes the wall to stiffen and become less compliant to stretching with each heartbeat.
In contrast, phosphate is actively produced by a combination of secretion of phosphate-containing compounds, including ATP, and by phosphatases that cleave phosphate to create a high phosphate concentration at the mineralization front. Alkaline phosphatase is a membrane-anchored protein that is a characteristic marker expressed in large amounts at the apical (secretory) face of active osteoblasts.
Criterion 1: Generalized joint hypermobility, as measured by the Beighton score Criterion 2: Minimum two of the following must be met: Symptoms that suggest a difference in connective tissue structure Unusually soft or velvety skin Mild skin hyperextensibility Unexplained striae distensae or rubae at the back, groins, thighs, breasts, and/or abdomen in adolescents, men, or pre-pubertal women without a history of significant gain or loss of body fat or weight Bilateral piezogenic papules of the heel Recurrent or multiple abdominal hernia(s) Atrophic scarring involving at least two sites and without the formation of truly papyraceous and/or hemosideric scars as seen in classical EDS Pelvic floor, rectal, and/or uterine prolapse in children, men, or nulliparous women without a history of morbid obesity or other known predisposing medical condition Dental crowding and a high or narrow palate Arachnodactyly Arm span-to-height ratio ≥1.05 Mitral valve prolapse (MVP) mild or greater based on strict echocardiographic criteria Aortic root dilatation with Z-score >+2 Positive family history Proof that these symptoms interfere with daily life Musculoskeletal pain in two or more limbs, recurring daily for at least 3 months Chronic, widespread pain for ≥3 months Recurrent joint dislocations or frank joint instability, in the absence of trauma Criterion 3: Exclusion of all other possible connective tissue disorders that may be the root cause of symptoms.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.